Breakthrough: Liver Cancer Survival Nearly Doubled

A significant advancement in treating intrahepatic cholangiocarcinoma (ICC), a severe form of liver cancer, has emerged from a pioneering Chinese study. This neoadjuvant therapy, involving a combination of chemotherapy, targeted therapy, and immunotherapy, was administered before surgery.

The study, involving 178 patients and conducted across 11 Chinese hospitals, showed remarkable results. Patients receiving the drug cocktail before surgery experienced a median event-free survival of 18 months, a substantial increase from the 8.7 months seen in patients who underwent surgery alone.

Tumor shrinkage was also notable, with 55 percent of patients in the drug-treatment group showing an objective response. This development is particularly crucial as ICC is often diagnosed at advanced stages, with a five-year survival rate of only 25-40 percent after surgery.

China bears a significant burden of ICC, accounting for over half of the global cases annually. The research, published in the New England Journal of Medicine, also indicated a promising trend in overall survival, with a 79 percent 24-month survival rate for the drug-protocol group versus 61 percent for the surgery-only group.